Copyright
©The Author(s) 2020.
World J Crit Care Med. Aug 7, 2020; 9(3): 43-53
Published online Aug 7, 2020. doi: 10.5492/wjccm.v9.i3.43
Published online Aug 7, 2020. doi: 10.5492/wjccm.v9.i3.43
Table 4 Use of antimicrobials in patients with ventilator-associated pneumonia vs those who did not develop the latter
| Antimicrobial treatment | Total (n = 263) | Non-VAP (n = 233) | VAP (n = 30) | P value |
| Antibacterial treatment | ||||
| Cephalosporins | 58 (22) | 47 (20.2) | 11 (36.7) | 0.03 |
| Days of cephalosporins12 | 6 (4, 9) | 6 (4, 9) | 4 (4, 10) | 0.856 |
| TZP | 86 (32.6) | 69 (29.6) | 17 (56.7) | 0.002 |
| Days of TZP2 | 6 (4, 9) | 7 (4, 9) | 6 (5, 7) | 0.895 |
| Aminoglycosides | 18 (6.8) | 14 (6) | 4 (13.3) | 0.134 |
| Days of aminoglycosides2 | 4 (3, 6) | 3 (3, 5) | 5 (4, 7) | 0.469 |
| Carbapenem | 228 (86.7) | 198 (85) | 30 (100) | 0.02 |
| Days of Carbapenem2 | 11 (7, 17) | 10 (6, 16) | 13 (10, 22) | 0.003 |
| Fluoroquinolones | 31 (11.8) | 23 (9.9) | 8 (26.7) | 0.006 |
| Days of fluoroquinolones2 | 10 (7, 14) | 11 (7, 14) | 9 (5, 15) | 0.586 |
| Vancomycin | 153 (58.2) | 130 (55.8) | 24 (80) | 0.01 |
| Days of vancomycin2 | 7 (4, 10) | 7 (4, 10) | 7 (4, 10) | 0.684 |
| Linezolid | 47 (17.8) | 39 (16.7) | 8 (26.7) | 0.205 |
| Days of linezolid2 | 9 (5, 12) | 8 (4, 11) | 14 (8, 21) | 0.05 |
| Clarithromycin | 68 (25.8) | 59 (25.3) | 9 (30) | 0.657 |
| Days of clarithromycin2 | 8 (7, 10) | 8 (6, 10) | 8 (8,10) | 0.505 |
| SMX/TMP | 68 (25.8) | 56 (24) | 12 (40) | 0.06 |
| Days of SMX/TMP2 | 8 (5, 13) | 12 (7, 21) | 12 (8, 14) | 0.577 |
| Colistin | 11 (4.2) | 7 (3) | 4 (13.3) | 0.02 |
| Days of colistin2 | 10 (4, 11) | 8 (3, 11) | 11 (8, 12) | 0.341 |
- Citation: Cornejo-Juárez P, González-Oros I, Mota-Castañeda P, Vilar-Compte D, Volkow-Fernández P. Ventilator-associated pneumonia in patients with cancer: Impact of multidrug resistant bacteria. World J Crit Care Med 2020; 9(3): 43-53
- URL: https://www.wjgnet.com/2220-3141/full/v9/i3/43.htm
- DOI: https://dx.doi.org/10.5492/wjccm.v9.i3.43